Get the Stockscreener App
22.96
7.16%
-1.77
After Hours:
22.96
Dianthus Therapeutics Inc stock is traded at $22.96, with a volume of 382.38K.
It is down -7.16% in the last 24 hours and down -15.09% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$24.73
Open:
$24.73
24h Volume:
382.38K
Relative Volume:
1.50
Market Cap:
$679.55M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-4.1422
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
+5.47%
1M Performance:
-15.09%
6M Performance:
-18.67%
1Y Performance:
+0.57%
1-Day Range:
$22.91
$24.97
1-Week Range:
$21.28
$24.97
52-Week Range:
$18.34
$33.77
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
857-201-2700
Address
300 TECHNOLOGY SQUARE, CAMBRIDGE
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
22.96 | 679.55M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 8%Here's Why - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Up 6.0% in January - MarketBeat
Octagon Capital Advisors LP Increases Stake in Dianthus Therapeu - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Increase in Short Interest - Defense World
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences - The Manila Times
Exclusive: Dianthus Therapeutics Reveals Next-Gen Autoimmune Pipeline at Elite Investor Summits - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.6%Here's Why - MarketBeat
Equities Analysts Issue Forecasts for DNTH FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DNTH FY2025 Earnings - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest - MarketBeat
A Dive Into Dianthus Therapeutics: Little To Move The Stock (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 5.5%Here's Why - MarketBeat
Barclays PLC Purchases 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Barclays PLC Acquires 33,185 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Dianthus Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.8%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8%Here's What Happened - MarketBeat
Jane Street Group LLC Takes $556,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stake Trimmed by Geode Capital Management LLC - Defense World
Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Position Raised by Barclays PLC - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of “Buy” by Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 2.5%Here's Why - MarketBeat
State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
State Street Corp Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
TD Cowen Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - Defense World
Forecasting The Future: 5 Analyst Projections For Dianthus Therapeutics - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen - MarketBeat
Wellington Management Group LLP Invests $1.47 Million in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James - Defense World
Raymond James Upgrades Dianthus Therapeutics (NASDAQ:DNTH) to Moderate Buy - MarketBeat
Charles Schwab Investment Management Inc. Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Charles Schwab Investment Management Inc. Boosts Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
MetLife Investment Management LLC Purchases 7,854 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asset Management L.P. Buys 263,500 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Janus Henderson Group PLC Acquires 273,670 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
30,000 Shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Acquired by Walleye Capital LLC - MarketBeat
HighVista Strategies LLC Purchases New Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Avidity Partners Management LP Increases Stake in Dianthus Thera - GuruFocus.com
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Quest Partners LLC Has $31,000 Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Braidwell LP Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Vestal Point Capital LP - MarketBeat
Great Point Partners LLC Lowers Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):